Shopping Cart 0
Cart Subtotal
USD 0

Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Vifor Pharma AG (Vifor Pharma) a subsidiary of Galenica Ltd is a healthcare service provider that discovers, develops, manufactures, and commercializes prescription and over the counter pharmaceutical products for the treatment of iron replacement therapy. The company offers products for treatment of iron deficiency, a range of non prescription products for the treatment of infectious diseases, and iron based phosphate binder for controlling serum phosphorus levels in patients with chronic kidney disease undergoing dialysis. Vifor Pharma's clinical programs concentrates on safety and efficacy of Broncho Vaxom for respiratory tract infections in children and in chronic obstructive pulmonary disease in adults; and uro vaxom for recurrent urinary tract infections. It has manufacturing facilities in Switzerland, the UK and Portugal. Vifor Pharma is headquartered in Glattbrugg, Switzerland.

Vifor Pharma AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Vifor Pharma AG, Medical Devices Deals, 2012 to YTD 2018 10

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Relypsa Secures USD2.6 Million in Venture Funding 13

Relypsa Raises USD 80 Million In Series C Financing 14

Relypsa Secures USD62.4 Million in Venture Funding 16

Partnerships 17

Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 17

Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 18

Probi Enters Into Co-Marketing Agreement With Vifor Pharma 19

Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 20

Licensing Agreements 21

Vifor-Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with Cara Therapeutics 21

Zeria Pharma Enters into Licensing Agreement with Vifor Pharma 23

Kissei Pharma Enters into Licensing Agreement with Vifor Fresenius Medical Care Renal Pharma 24

Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 25

Vifor Pharma Enters into Licensing Agreement with ChemoCentryx 26

Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 27

Vifor Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with OPKO Health for Rayaldee 28

Vifor Pharma Expands Licensing Agreement with Roche 29

Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 30

Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 31

Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 32

Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 33

Equity Offering 34

Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 34

Relypsa Raises USD172 Million in Public Offering of Shares 35

Relypsa Completes Public Offering Of Shares For USD 101.2 Million 37

Relypsa Completes IPO For USD 86.7 Million 39

Debt Offering 41

Vifor Pharma Raises USD473.6 Million in Public Offering of 0.75% Bonds Due 2022 41

Acquisition 42

Vifor Pharma to Acquire 14.6% Stake in Chemocentryx from GlaxoSmithKline 42

Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 44

Relypsa May Sell Itself 46

Vifor Pharma AG-Key Competitors 47

Vifor Pharma AG-Key Employees 48

Vifor Pharma AG-Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Recent Developments 51

Financial Announcements 51

Aug 08, 2018: Vifor Pharma Group reports strong H1 2018 results, raises full-year guidance 51

Mar 15, 2018: Vifor Pharma Group Reports Strong 2017 Results, Exceeding Raised Guidance 55

Aug 08, 2017: Vifor Pharma Reports Strong H1 2017 Results And Raises Guidance 60

Corporate Communications 61

Sep 20, 2018: Vifor Pharma announces changes in management 61

Mar 29, 2018: Vifor Pharma to Propose Jacques Theurillat as Board Member 62

Government and Public Interest 63

Feb 20, 2017: Vifor Pharma and ECCO Announces One-Year Research Grant for Iron Deficiency 63

Clinical Trials 64

Feb 08, 2018: Vifor Pharma Ferroportin Inhibitor Enters Phase-I Clinical Trial 64

Appendix 65

Methodology 65

About GlobalData 65

Contact Us 65

Disclaimer 65


List Of Figure

List of Figures

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Vifor Pharma AG, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Vifor Pharma AG, Pharmaceuticals & Healthcare, Key Facts 2

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vifor Pharma AG, Deals By Therapy Area, 2012 to YTD 2018 9

Vifor Pharma AG, Medical Devices Deals, 2012 to YTD 2018 10

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Relypsa Secures USD2.6 Million in Venture Funding 13

Relypsa Raises USD 80 Million In Series C Financing 14

Relypsa Secures USD62.4 Million in Venture Funding 16

Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 17

Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 18

Probi Enters Into Co-Marketing Agreement With Vifor Pharma 19

Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 20

Vifor-Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with Cara Therapeutics 21

Zeria Pharma Enters into Licensing Agreement with Vifor Pharma 23

Kissei Pharma Enters into Licensing Agreement with Vifor Fresenius Medical Care Renal Pharma 24

Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 25

Vifor Pharma Enters into Licensing Agreement with ChemoCentryx 26

Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 27

Vifor Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with OPKO Health for Rayaldee 28

Vifor Pharma Expands Licensing Agreement with Roche 29

Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 30

Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 31

Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 32

Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 33

Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 34

Relypsa Raises USD172 Million in Public Offering of Shares 35

Relypsa Completes Public Offering Of Shares For USD 101.2 Million 37

Relypsa Completes IPO For USD 86.7 Million 39

Vifor Pharma Raises USD473.6 Million in Public Offering of 0.75% Bonds Due 2022 41

Vifor Pharma to Acquire 14.6% Stake in Chemocentryx from GlaxoSmithKline 42

Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 44

Relypsa May Sell Itself 46

Vifor Pharma AG, Key Competitors 47

Vifor Pharma AG, Key Employees 48

Vifor Pharma AG, Other Locations 49

Vifor Pharma AG, Subsidiaries 49

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Vifor Pharma AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.